Search Results

You are looking at 1 - 10 of 122 items for :

  • major depressive disorder x
Clear All
Open access

M Krivosova, P Kusnir, M Kertys, M Mestanik, I Tonhajzerova, I Hrtanek, I Ondrejka and J. Mokry

disorder undergoing no pharmacological therapy. Neuropsychiatr Dis Treat. 2015;11:2253-8. 15. Demircan F, Gözel N, Kılınç F, Ulu R, Atmaca M. The Impact of Red Blood Cell Distribution Width and Neutrophil/Lymphocyte Ratio on the Diagnosis of Major Depressive Disorder. Neurol Ther. 2016;5(1):27-33. 16. Balta S, Demırkol S, Kucuk U. The platelet lymphocyte ratio may be useful inflammatory indicator in clinical practice. Hemodial Int. 2013;17(4):668-9. 17. Mazza MG, Lucchi S, Tringali AGM, Rossetti A, Botti ER, Clerici M. Neutrophil/lymphocyte ratio and

Open access

Tewin Tencomnao, Thapanut Sritharathikhun and Sarawut Suttirat

depression? J Affect Disord. 2003; 77: 273-5. 13. Nobile M, Cataldo MG, Giorda R, Battaglia M, Baschirotto C, Bellina M, et al. A case-control and family-based association study of the 5-HTTLPR in pediatric-onset depressive disorders. Biol Psychiatry. 2004; 56:292-5. 14. Hoefgen B, Schulze TG, Ohlraun S, von Widdern O, Höfels S, Gross M, et al. The power of sample size and homogenous sampling: association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorder. Biol Psychiatry. 2005; 57

Open access

B Zalar, A Blatnik, A Maver, Z Klemenc-Ketiš and B Peterlin

depressive disorder (MDD) is a field of study that has baffled many researchers; while it has shown great promise, it has actually yielded very few tangible results. Major depressive disorder has long been known to be moderately heritable. Twin studies have repeatedly shown the heritability of major depression to be about 37.0-38.0% [ 2 , 3 ]. Different approaches to studying the genetics of MDD have so far been consistent only in their inconsistency; linkage studies, candidate gene approaches, studies of gene-environment interaction, and more recent genome

Open access

Th Moica, I Gabos Grecu, Marieta Gabos Grecu, Melinda Ferencz, Elena Gabriela Buicu, Andreea Sălcudean and C Gabos Grecu

References 1. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from Major Depressive Disorder during 15 years of observational follow-up. Am J Psychiatry. 1999;156:1000-6. 2. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry. 2006;163:28-40. 3. Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for

Open access

Lay-Hoong Lian, Ai-Chin Loke, Nor Z Zainal and Zahurin Mohamed

. Psychiatr Genet. 2005; 15:7-11. 12. Hong CJ, Tsai SJ, Wang YC. Association between tryptophan hydroxylase gene polymorphism (A218C) and schizophrenic disorders. Schizophr Res. 2001; 49: 59-63. 13. Tan EC, Chan AO, Tan CH, Mahendran R, Wang A, Chua HC. Case-control and linkage disequilibrium studies of the tryptophan hydroxylase gene polymorphisms and major depressive disorder. Psychiatr Genet. 2003; 13:151-4. 14. Bellivier F, Leboyer M, Courtet P, Buresi C, Beaufils B, Samolyk D, et al. Association between the tryptophan

Open access

Vineta Viktorija Vinogradova, Jeļena Vrubļevska and Elmārs Rancāns

-vignette survey. PLoS ONE , 7 (12), e52429. Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Pike, C. T., Kessler, R. C. (2015). The Economic burden of adults with major depressive disorder in the United States (2005 and 2010). J. Clin. Psychiatry, 76 (2), 155–162. Hall, J. A., Irish, J. T., Roter, D. L., Ehrlich, C. M., Miller, L. H. (1994). Gender in medical encounters: An analysis of physician and patient communication in a primary care setting. Health Psychology , 13 (5), 384–392. Honigfeld, L., Macary, S. J., Grasso, D. J. (2017). A clinical

Open access

M Oppa, D Cesnekova, G Nosalova and I Ondrejka

REFERENCES 1. Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment. 2014; 10: 1297-1307. 2. Andrade L, Caraveo-Anduaga JJ, Berglund P et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res. 2003; 12 (3): 165. 3. Farsky I, Smetanka A, Dubinska S. Spirituality of patients with selected psychiatric disorders

Open access

M. Oppa, I. Ondrejka, D. Cesnekova, I. Tonhajzerova and G. Nosalova

References [1] Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment. 2014;10:1297–1307. [2] Farsky I, Smetanka A, Dubinska S. Spiritualita pacientov s vybranymi psychiatrickymi diagnozami. Osetrovatelstvi a porodni asistence. 2012;3(3):433–441. [3] Nemeroff CB. Prevalence and management of treatment resistant depression. J Clin Psychiatry. 2007;68(Suppl 8):17–25. [4] Serreti A, Chiesa A. Treatment-emergent sexual dysfunction

Open access

Theodor Moica, Iosif Gabos Grecu, Gabriela Elena Buicu, Melinda Ferencz, Marieta Gabos Grecu, Andreea Sălcudean and Cosmin Octavian Popa

volume in MDD. European Journal of Psychotraumatology. 2012;3(1). 12. Dedovic KEV, Duchesne A, Lue S, et al. Cortisol awakening response and hippocampal volume: vulnerability for major depressive disorder? Biol Psychiatry. 2010;68(9):847-53. 13. Holsboer F. Redesigning antidepressant drug discovery. Dialogues Clin Neurosci. 2014;16(1):5-7. 14. Mossner R, Mikova O, Koutsilieri E, et al. Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J Biol Psychiatry. 2007

Open access

Andrej Ilankovic, Aleksandar Damjanovic, Vera Ilankovic, Srdjan Milovanovic, Dusan Petrovic and Nikola Ilankovic

References 1. Miret M, Ayuso-Mateos JL, Sanchez-Moreno J, Vieta E: Depressive disorders and suicide: Epidemiology, risk factors, and burden. Neurosci Biobehav Rev. 2013. 2. Rössler W, Salize HJ, Van Os J, Riecher-Rössler A: Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005; 15: 399-409. 3. Benca RM, Obermeyer WH, Thisted RA, Gillin JC: Sleep and psychiatric disorders. A meta-analysis. Arch Gen Psychiatry. 1992; 49: 651-68. 4. Tsuno N, Besset A